Merck & Co. (MRK)
Health Care · Integrated Pharmaceuticals & Vaccines · NYSE
Global pharmaceutical and vaccine leader with oncology, infectious disease, and animal health franchises, anchored by blockbuster immunotherapy Keytruda.
What Merck & Co. does
Merck is a global healthcare company that discovers, develops, manufactures and markets innovative prescription medicines, biologic therapies, vaccines, and animal health products. The company operates through two primary segments: Pharmaceutical (human health pharmaceuticals and vaccines) and Animal Health (veterinary pharmaceuticals, vaccines, and digital health management solutions). Its pharmaceutical products are sold to wholesalers, retailers, hospitals, government agencies, and managed care providers, while animal health products are sold to veterinarians, distributors, farmers, and pet owners worldwide.
Themes: ["Oncology / immuno-oncology","Vaccines / immunization","Infectious disease","Animal health","Checkpoint inhibitor therapy","Combination cancer therapies","Diabetes / metabolic disease"]
Fundamentals
- Price$125.07 as of 2026-07-09 close
- Market cap$310.1B as of 2026-07-10
- 1-year return+49.4% as of 2026-07-09 close
- P/E34.71 as of 2026-07-10
- Net margin+13.6% as of 2026-07-10
- Gross margin+78.1% as of 2026-07-10
- ROE+17.9% as of 2026-07-10
- Debt / equity1.07 as of 2026-07-10
- Revenue growth (YoY)+2.9% as of 2026-07-10
- Revenue CAGR (3y)+3.1% SEC XBRL
- Beta0.21 as of 2026-07-10
Dividend: yield +2.7%; 5-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Heavy dependence on Keytruda revenue ($31.7B in 2025, ~49% of pharmaceutical sales) with patent cliff and competitive biosimilar pressure looming as exclusivity expires","R&D expense spike and acquisition activity (Cidara Therapeutics, $8.8B in Q1 2026) signaling pipeline challenges and need for external innovation","Competitive pressure in oncology and vaccines from multiple rivals; demonstrated by quarterly loss in Q1 2026 despite modest revenue growth, with net margin compression and significant R&D write-offs"]
Competitors & peers
- Roche/Genentech
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.